PriceTargets.com logo

Nasus Pharma - NSRX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.50
  • Forecasted Upside: 343.26%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.82 As of 11/6/2026 05:10 PM ET
▼ -0.09 (-3.09%)

This chart shows the closing price for NSRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Nasus Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NSRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NSRX

Analyst Price Target is $12.50
▲ +343.26% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Nasus Pharma in the last 3 months. The average price target is $12.50, with a high forecast of $18.00 and a low forecast of $7.00. The average price target represents a 343.26% upside from the last price of $2.82.

This chart shows the closing price for NSRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Nasus Pharma.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/16/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/14/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/12/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/10/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/11/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/9/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/8/2026
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/7/2026

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/30/2026Maxim GroupInitiated CoverageBuy$7.00
3/26/2026Citizens JmpLower TargetMarket Outperform ➝ Market Outperform$19.00 ➝ $18.00
(Data available from 11/7/2021 forward)

News Sentiment Rating

0.27 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/11/2026
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/11/2026
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/10/2026
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/10/2026
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/9/2026
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/8/2026
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/8/2026
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/7/2026

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Nasus Pharma logo
Nasus Pharma Ltd. is a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions. Nasus Pharma Ltd. is based in TEL AVIV, Israel.
Read More

Today's Range

Now: $2.82
Low: $2.78
High: $3.01

50 Day Range

MA: $3.47
Low: $2.82
High: $4.10

52 Week Range

Now: $2.82
Low: $1.98
High: $9.50

Volume

6,993 shs

Average Volume

17,027 shs

Market Capitalization

$33.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

4.25

Frequently Asked Questions

What sell-side analysts currently cover shares of Nasus Pharma?

The following Wall Street analysts have issued stock ratings on Nasus Pharma in the last twelve months: Citizens Jmp, and Maxim Group.
View the latest analyst ratings for NSRX.

What is the current price target for Nasus Pharma?

0 Wall Street analysts have set twelve-month price targets for Nasus Pharma in the last year. Their average twelve-month price target is $12.50, suggesting a possible upside of 343.3%. Citizens Jmp has the highest price target set, predicting NSRX will reach $18.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $7.00 for Nasus Pharma in the next year.
View the latest price targets for NSRX.

What is the current consensus analyst rating for Nasus Pharma?

Nasus Pharma currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NSRX will outperform the market and that investors should add to their positions of Nasus Pharma.
View the latest ratings for NSRX.

What other companies compete with Nasus Pharma?

Other companies that are similar to Nasus Pharma include Jyong Biotech, Zentalis Pharmaceuticals, Cardiol Therapeutics, ProMetic Life Sciences and Silverback Therapeutics. Learn More about companies similar to Nasus Pharma.

How do I contact Nasus Pharma's investor relations team?

Nasus Pharma's physical mailing address is 29 Harakevet ST, Tel Aviv - Yafo, 6618003. The company's listed phone number is 972-3573-6632 and its investor relations email address is [email protected]. The official website for Nasus Pharma is www.nasuspharma.com. Learn More about contacing Nasus Pharma investor relations.